ClariVest Asset Management’s Haemonetics HAE Stock Holding History

ClariVest Asset Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$2.5M	Hold	30,191	–	–	0.25%	98
2024 Q2	$2.5M	Buy	30,191 +27	+0.1%	+$2.38K	0.25%	98
2024 Q1	$2.57M	Sell	30,164 -169	-0.6%	-$13.3K	0.27%	99
2023 Q4	$2.59M	Sell	30,333 -1,718	-5%	-$149K	0.14%	107
2023 Q3	$2.87M	Buy	32,051 +32	+0.1%	+$2.86K	0.16%	94
2023 Q2	$2.73M	Sell	32,019 -5,104	-14%	-$432K	0.14%	104
2023 Q1	$3.07M	Buy	37,123 +11,837	+47%	+$958K	0.14%	126
2022 Q4	$1.99M	Sell	25,286 -105	-0.4%	-$8.44K	0.1%	165
2022 Q3	$1.88M	Buy	+25,391	New	+$1.82M	0.09%	171
2020 Q3	–	Sell	-28,852	Closed	-$2.58M	–	794
2020 Q2	$2.58M	Buy	28,852 +21,724	+305%	+$2.19M	0.07%	195
2020 Q1	$711K	Buy	+7,128	New	+$773K	0.02%	353
2019 Q1	–	Sell	-89,968	Closed	-$9M	–	735
2018 Q4	$9M	Buy	89,968 +28,392	+46%	+$2.98M	0.19%	106
2018 Q3	$7.06M	Buy	61,576 +18,087	+42%	+$1.87M	0.12%	124
2018 Q2	$3.9M	Buy	43,489 +43,482	+621,171%	+$3.67M	0.07%	235
2018 Q1	$1K	Hold	7	–	–	﹤0.01%	683
2017 Q4	$0	Buy	+7	New	+$369	﹤0.01%	736

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

ClariVest Asset Management's HAE Position: Q3 2024 in Review

ClariVest Asset Management held its Haemonetics (HAE) position steady in Q3 2024 at 30,191 shares worth $2.5M. The position accounts for 0.25% of the portfolio, ranked #98.

ClariVest Asset Management first reported a position in HAE in Q4 2017 and has held it in 16 quarters since. The position peaked at $9M in Q4 2018. 306 funds tracked by Wall St. Rank hold HAE as of Q3 2024.

ClariVest Asset Management held 30,191 shares of Haemonetics worth $2.5M as of Q3 2024.
ClariVest Asset Management left its Haemonetics share count unchanged in Q3 2024.
Haemonetics made up 0.25% of ClariVest Asset Management's portfolio in Q3 2024, its #98 holding.
ClariVest Asset Management first reported a position in Haemonetics in Q4 2017 and has held it in 16 quarters since.
ClariVest Asset Management's Haemonetics position peaked at $9M in Q4 2018.
306 funds tracked by Wall St. Rank held Haemonetics as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.